Hyaluronic Acid - Adverse effects
Research News and Information

Sunday, November 22, 2009

Postoperative intra-abdominal collections using a sodium hyaluronate-carboxymethylcellulose (HA-CMC) barrier at the time of laparotomy for ovarian, fallopian tube, or primary peritoneal cancers.

6 Sep 2009 OBJECTIVES: To determine whether HA-CMC was associated with the development of postoperative intra-abdominal collections in patients undergoing laparotomy for ovarian, fallopian tube, or primary peritoneal malignancies. METHODS: We retrospectively ... Read more...

Pseudodistal ureteral stone resulting from calcified Deflux implantation.

16 Jul 2009 Vesicoureteral reflux (VUR) is a common clinical problem affecting 1% of pediatric patients. Subureteral endoscopic injection of dextranomer/hyaluronic acid (Deflux) is a minimally invasive treatment option for VUR that is rapidly gaining ... Read more...

A double-blind, randomized, saline-controlled study of the efficacy and safety of EUFLEXXA for treatment of painful osteoarthritis of the knee, with an open-label safety extension (the FLEXX trial).

15 Jun 2009 OBJECTIVE: To report the FLEXX trial, the first well-controlled study assessing the safety and efficacy of Euflexxa (1% sodium hyaluronate; IA-BioHA) therapy for knee osteoarthritis (OA) at 26 weeks. METHODS: This was a randomized, double-blind, ... Read more...

Latest indexed articles for 'Hyaluronic Acid - Adverse effects'

These are the very latest articles for this heading:

• Postoperative intra-abdominal collections using a sodium hyaluronate-carboxymethylcellulose (HA-CMC) barrier at the time of laparotomy for ovarian, fallopian tube, or primary peritoneal cancers. 6 Sep 2009
• Transient, complete loss of vision secondary to posterior diffusion of an ophthalmic viscosurgical device-lidocaine solution during complicated phacoemulsification. 30 Jul 2009
• Pseudodistal ureteral stone resulting from calcified Deflux implantation. 16 Jul 2009
• Periurethral non-animal stabilized hyaluronic acid/dextranomer injections: efficacy and formation of granuloma/sterile abscess. 6 Jul 2009
• A double-blind, randomized, saline-controlled study of the efficacy and safety of EUFLEXXA for treatment of painful osteoarthritis of the knee, with an open-label safety extension (the FLEXX trial). 15 Jun 2009
• Hyaluronic acid fillers: a comprehensive review. 2 May 2009
• Volumizing the brow with hyaluronic acid fillers. 29 Apr 2009
• The efficacy of hyaluronic acid in the treatment of osteoarthritis of the trapeziometacarpal joint. 29 Apr 2009
• Assessment of a new hyaluronic acid filler. double-blind, randomized, comparative study between Puragen and Captique in the treatment of nasolabial folds. 29 Apr 2009
• Clinical efficacy of a Ginkgo biloba extract in the topical treatment of allergic conjunctivitis. 29 Apr 2009
• [Long-term complications after injection of permanent tissue-fillers to the lips] 18 Apr 2009
• Phase I study of a new radiosensitizer containing hydrogen peroxide and sodium hyaluronate for topical tumor injection: a new enzyme-targeting radiosensitization treatment, Kochi Oxydol-Radiation Therapy for Unresectable Carcinomas, Type II (KORTUC II). 27 Feb 2009
• Effect of hyaluronic acid in symptomatic hip osteoarthritis: a multicenter, randomized, placebo-controlled trial. 27 Feb 2009
• A systematic review of conflicting meta-analyses in orthopaedic surgery. 26 Feb 2009
• Effective treatment of a injected hyaluronic acid-induced Tyndall effect with a 1064-nm Q-switched Nd:YAG laser. 17 Feb 2009
• Complications in fillers and Botox. 30 Jan 2009
• Extensive granulomatous reaction occurring 1.5 years after DermaLive injection. 30 Jan 2009
• Recurrent urticarial vasculitis related to nonanimal hyaluronic acid skin filler injection. 30 Jan 2009
• Risk of severe adverse reactions to an injectable filler based on a fixed combination of hydroxyethylmethacrylate and ethylmethacrylate with hyaluronic acid. 30 Jan 2009
• By the way, doctor. I have been taking capsules containing hyaluronic acid for my knees. Is there any downside to this medication? 30 Jan 2009

See a longer list of these articles.

Technical information about 'Hyaluronic Acid'

Definition: A natural high-viscosity mucopolysaccharide with alternating beta (1-3) glucuronide and beta (1-4) glucosaminidic bonds. It is found in the UMBILICAL CORD, in VITREOUS BODY and in SYNOVIAL FLUID. A high urinary level is found in PROGERIA.

Chemical name: Hyaluronic acid

Registry Number: 9004-61-9

Descriptor UI: D006820

Alternative terms: Hyaluronic Acid; Acid, Hyaluronic; Amvisc; Bausch and Lomb Brand of Sodium Hyaluronate; Biolon; Akorn, Inc. Brand of Sodium Hyaluronate; Etamucine; Hyaluronan; Hyvisc; Anika Therapeutics Brand of Sodium Hyaluronidate; Luronit; Sodium Hyaluronate; Hyaluronate, Sodium; Hyaluronate Sodium; Amo Vitrax; Vitrax, Amo; Advanced Medical Optics, Inc. Brand of Sodium Hyaluronate; Healon; Advanced Medical Optics Brand of Sodium Hyaluronidate;

Allowable Qualifiers: administration & dosage; adverse effects; analogs & derivatives; analysis; antagonists & inhibitors; biosynthesis; blood; cerebrospinal fluid; chemical synthesis; classification; deficiency; diagnostic use; economics; genetics; history; immunology; isolation & purification; metabolism; pharmacokinetics; pharmacology; physiology; poisoning; radiation effects; secretion; standards; supply & distribution; therapeutic use; toxicity; urine; chemistry; contraindications; agonists; ultrastructure;

Pharmacological Action: Viscosupplements; Adjuvants, Immunologic;

Tree Number: D09.698.373.475;

History Note: 2002; for BIOLON use POLYMETHYL METHACRYLATE 1977-2001